Biodesix (BDSX) Net Cash Flow (2019 - 2026)

Biodesix (BDSX) has 8 years of Net Cash Flow data on file, last reported at $6.6 million in Q1 2026.

• Quarterly Net Cash Flow rose 176.2% year-over-year to $6.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.0 million (up 30.4% YoY) and the FY2025 annual result came in at -$7.3 million, down 18507.69% from the prior year.
• Net Cash Flow climbed to $6.6 million in Q1 2026, from $2.4 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $30.7 million in Q2 2024 to a low of -$17.8 million in Q1 2023.
• A 5-year average of -$419882.4 and a median of -$4.1 million in 2025 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2022 — Net Cash Flow jumped 1092.06% — and 2024, when it tumbled 544.8%.
• Tracing BDSX's Net Cash Flow over 5 years: stood at $27.9 million in 2022, then sank by 76.91% to $6.4 million in 2023, then sank by 180.09% to -$5.2 million in 2024, then surged by 146.17% to $2.4 million in 2025, then surged by 176.33% to $6.6 million in 2026.
• The last three Net Cash Flow figures came in at $6.6 million (Q1 2026), $2.4 million (Q4 2025), and -$4.1 million (Q3 2025), per Business Quant data.